share_log

新銳醫藥：截至二零二四年六月三十日止六個月之中期業績公告

NEW RAY MEDIC: INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED 30 JUNE 2024

HKEX ·  Aug 28, 2024 20:34

Summary by Moomoo AI

新銳醫藥國際控股有限公司公布截至2024年6月30日止六個月的中期業績，顯示收益較去年同期下降46.1%，至約1.67億港元。公司擁有人應佔虧損淨額減少69.4%，至約408.8萬港元。該期間不派發任何中期股息。公司指出收益減少主要由於中國內地加強抗菌藥物分層分類管理政策，導致主要產品需求下降。此外，公司於期內進行了多項投資活動，包括收購目標公司股權及參與基石投資等。公司亦提到，期內無重大訴訟、仲裁或申索，並已遵守企業管治守則。董事會主席、行政總裁兼執行董事王秋勤女士表示，公司將繼續檢討結構並尋找合適人選出任主席一職。
新銳醫藥國際控股有限公司公布截至2024年6月30日止六個月的中期業績，顯示收益較去年同期下降46.1%，至約1.67億港元。公司擁有人應佔虧損淨額減少69.4%，至約408.8萬港元。該期間不派發任何中期股息。公司指出收益減少主要由於中國內地加強抗菌藥物分層分類管理政策，導致主要產品需求下降。此外，公司於期內進行了多項投資活動，包括收購目標公司股權及參與基石投資等。公司亦提到，期內無重大訴訟、仲裁或申索，並已遵守企業管治守則。董事會主席、行政總裁兼執行董事王秋勤女士表示，公司將繼續檢討結構並尋找合適人選出任主席一職。
New Ray Medicine International Holdings Limited announced its interim performance for the six months ending June 30, 2024, showing a 46.1% decrease in revenue compared to the same period last year, to approximately 16.7 billion Hong Kong dollars. The net loss attributable to owners of the company decreased by 69.4% to approximately 4.088 million Hong Kong dollars. No interim dividends were declared during this period. The company attributed the decrease in revenue mainly to the strengthened hierarchical classification management policy of antimicrobial drugs in mainland China, leading to a decline in demand for its main products. In addition, the company conducted multiple investment activities during the period, including acquisition of equity interests in target companies and participation in cornerstone investments. The company also mentioned that there...Show More
New Ray Medicine International Holdings Limited announced its interim performance for the six months ending June 30, 2024, showing a 46.1% decrease in revenue compared to the same period last year, to approximately 16.7 billion Hong Kong dollars. The net loss attributable to owners of the company decreased by 69.4% to approximately 4.088 million Hong Kong dollars. No interim dividends were declared during this period. The company attributed the decrease in revenue mainly to the strengthened hierarchical classification management policy of antimicrobial drugs in mainland China, leading to a decline in demand for its main products. In addition, the company conducted multiple investment activities during the period, including acquisition of equity interests in target companies and participation in cornerstone investments. The company also mentioned that there were no significant litigations, arbitrations, or claims during the period, and it has complied with corporate governance practices. Ms. Wang Qiuqin, the Chairperson of the board of directors, Chief Executive Officer, and Executive Director, expressed that the company will continue to review its structure and seek suitable candidates to appoint as the Chairperson.

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Related Stocks Related Stocks
    Symbol Mini Chart Price
    FANGZHOU JIANKE
    06086
    -- 4.490
    SINOPHARM
    01099
    -- 20.550
    TYCOON GROUP
    03390
    -- 3.700
    AUSUPREME
    02031
    -- 0.228
    YSB
    09885
    -- 7.150
    Log In for the Full List
    Reassessing Chinese Assets
    Following the introduction of China's groundbreaking DeepSeek technology, Wall Street giants have revised their investment outlooks for the Chinese market.
    Discussing
    Big Tech’s earnings season in full swing! Nvidia is the only one left
    On Thursday, $Amazon (AMZN.US)$ stock fell after the firm reported Q4 adjusted earnings of $1.86/share, vs estimates of $1.50/share, on reve Show More
    AMZN earnings preview: Grab rewards by guessing the opening price!